Navigation Links
Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
Date:3/9/2009

CINCINNATI, March 9 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced Chief Operating Officer Christopher Bergen will participate in the Barclays Capital Global Healthcare Conference on March 10 as well as the Raymond James 30th Annual Institutional Investors Conference on March 11.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )

Barclays Capital Global Healthcare Conference

The Barclays Capital Global Healthcare Conference will be held March 10-11 at the Loews Miami Beach Hotel in Miami. The Kendle presentation by Mr. Bergen is scheduled for Tuesday, March 10 at 9 a.m. Eastern Time.

The presentation will be Webcast and may be accessed at www.kendle.com in the "Investors Events & Presentations" section or at http://cc.talkpoint.com/barc002/030909a_rb/?entity=107_X2FCIEE. Slides will be available by 7 a.m. on the day of the presentation at www.kendle.com in the "Investors Events & Presentations" section.

Raymond James 30th Annual Institutional Investors Conference

The Raymond James 30th Annual Institutional Investors Conference will be held March 9-11 at the JW Marriott in Orlando, Fla. The Kendle presentation by Mr. Bergen is scheduled for Wednesday, March 11 at 7:30 a.m. Eastern Time.

The presentation will be Webcast and may be accessed at www.kendle.com in the "Investors Events & Presentations" section or at http://wsw.com/webcast/rj43/kndl/. Slides will be available by 6 a.m. on the day of the presentation at www.kendle.com in the "Investors Events & Presentations" section.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Kendle was recognized by FORTUNE magazine as one of the 100 fastest- growing companies in the United States for 2008. The company also has been recognized as "Top CRO to Work With" in the CenterWatch 2007 survey of U.S. investigative sites and among the "Top CROs in Europe" in the 2008 survey of European sites.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call
2. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
3. Kendle to Present at the 2008 Credit Suisse Health Care Conference
4. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
5. Kendle Named a Best Place to Work in Greater Cincinnati
6. Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
7. Kendle Named to FORTUNE List of 100 Fastest-Growing Companies for 2008
8. Kendle to Present at the UBS Global Life Sciences Conference
9. Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast
10. Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress
11. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/24/2016)... -- Regular discussions on a range of subjects including policies, debt ... said Poloz. Speaking at a lecture to the ... pointed to the country,s inflation target, which is set by ... "In certain areas there needs to ... goals, why not sit down and address strategy together?" ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
Breaking Biology Technology:
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
(Date:3/18/2016)... March 18, 2016 --> ... Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter ... companies in the border security market and the continuing migration ... Europe has led visiongain to publish ... success. --> defence & security companies in ...
Breaking Biology News(10 mins):